Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Portola’s Betrixaban Data Pass Muster With FDA?

This article was originally published in The Pink Sheet Daily

Executive Summary

Portola says that it does not expect it will need to do a second Phase III study to get FDA approval for betrixaban, after missing major endpoint in APEX, but analysts have doubts.


Related Content

Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Enriched Trials Not Just About Marker-Positive Patients, FDA Says
Clinical Trial Enrichment Could Require Post-Market Studies, Labeling To Address Shortcomings
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin


Related Companies